Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Immunovant (IMVT) and Biogen (BIIB)

Tipranks - Tipranks - Fri Apr 17, 6:14AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medtronic (MDT), Immunovant (IMVT) and Biogen (BIIB).

Claim 30% Off TipRanks

Medtronic (MDT)

Piper Sandler analyst Matthew O’Brien reiterated a Hold rating on Medtronic today and set a price target of $91.00. The company’s shares closed last Wednesday at $87.10.

According to TipRanks.com, O’Brien is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.7% and a 34.8% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Shoulder Innovations, Inc., and Adagio Medical Holdings. ;'>

Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $107.68, which is a 22.6% upside from current levels. In a report issued on April 6, Stifel Nicolaus also maintained a Hold rating on the stock with a $95.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Immunovant (IMVT)

Piper Sandler analyst Yasmeen Rahimi reiterated a Buy rating on Immunovant today and set a price target of $66.00. The company’s shares closed last Wednesday at $27.43.

According to TipRanks.com, Rahimi is a 5-star analyst with an average return of 31.2% and a 48.4% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Praxis Precision Medicines, and Crinetics Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunovant with a $41.57 average price target, which is a 54.6% upside from current levels. In a report issued on April 6, LifeSci Capital also maintained a Buy rating on the stock with a $42.00 price target.

Biogen (BIIB)

In a report released today, Yatin Suneja from Guggenheim reiterated a Buy rating on Biogen, with a price target of $246.00. The company’s shares closed last Wednesday at $180.54.

According to TipRanks.com, Suneja is a 5-star analyst with an average return of 32.4% and a 59.0% success rate. Suneja covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $206.61 average price target, implying a 15.2% upside from current levels. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $213.00 price target.

Read More on MDT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).